In last trading session, Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) saw 0.85 million shares changing hands with its beta currently measuring 2.37. Company’s recent per share price level of $1.19 trading at $0.0 or 0.00% at ring of the bell on the day assigns it a market valuation of $270.33M. That closing price of ADAP’s stock is at a discount of -72.27% from its 52-week high price of $2.05 and is indicating a premium of 64.71% from its 52-week low price of $0.42. Taking a look at company’s average trading volume volume of 1.59 million if we extend that period to 3-months.
Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) trade information
In the last five days ADAP remained trading in the green while hitting it’s week-highest on Thursday, 05/02/24 when the stock touched $1.19 price level, adding 4.8% to its value on the day. Adaptimmune Therapeutics Plc ADR’s shares saw a change of 50.06% in year-to-date performance and have moved 10.70% in past 5-day. Adaptimmune Therapeutics Plc ADR (NASDAQ:ADAP) showed a performance of -11.85% in past 30-days.
Adaptimmune Therapeutics Plc ADR (ADAP) estimates and forecasts
Statistics highlight that Adaptimmune Therapeutics Plc ADR is scoring comparatively higher than the scores of other players of the relevant industry. The company added 120.37% of value to its shares in past 6 months, showing an annual growth rate of 22.22% while that of industry is 12.80. Apart from that, the company came raising its revenue forecast for fiscal year 2024. This year revenue growth is estimated to rise 24.40% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 10.73M for the same. And 7 analysts are in estimates of company making revenue of 25.91M in the next quarter. Company posted 47.6M and 5.13M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 10.30% during past 5 years. In 2024, company’s earnings growth rate is likely to be around -467.56% while estimates for its earnings growth in next 5 years are of 1.00%.
ADAP Dividends
Adaptimmune Therapeutics Plc ADR is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
